Johnson & Johnson applied for FDA approval for the use of its cancer drug Doxil combined with Sanofi-Aventis' Taxotere in women who have advanced breast cancer. The combination therapy is intended for patients who already received anthracycline, a standard chemotherapy medicine, J&J unit Ortho Biotech Products said.

Full Story:

Related Summaries